Multispan and Promega streamlining GPCR screening

Promega and San Francisco area-based Multispan have agreed to co-develop assay tools for G-protein coupled receptor (GPCR) screening by combining Multispan GPCR cell lines and Promega bioluminescent technologies.

Register for free to listen to this article
Listen with Speechify
0:00
5:00
MADISON, Wis.—Promega and San Francisco area-based Multispan have agreed to co-develop assay tools for G-protein coupled receptor (GPCR) screening by combining Multispan GPCR cell lines and Promega bioluminescent technologies. The first tools will support cell lines and cAMP-Glo Assay for quantification of signal. Additional tools will be developed for cell-based assay detection. This combination of validated biologic components and a sensitive and dynamic luminescence assay detection technology for high-throughput screening reportedly will provide increased speed and efficiency in GPCR drug screening."Pre-optimized protocols will reduce assay development times, from months to days, helping deliver better GPCR targeted drugs faster," according to John Watson, marketing director of pharma/biotech at Promega. "Our suite of assay tools can be combined with Multispan's validated GPCR cell lines to provide turnkey solutions for drug discovery scientists."


Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue